Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use

European Journal of Contraception and Reproductive Health Care

Volumn 16, Issue 2, 2011, Pages 85-94

  Rad, Mandana ^a   Kluft, Cornelis ^a,b   De Kam, Marieke L ^a   Meijer, Piet ^b   Cohen, Adam F ^a   Grubb, Gary S ^c   Constantine, Ginger D ^c   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b TNO   (Netherlands)

^c PFIZER INC   (United States)

Author keywords

Continuous oral contraceptive; Ethinylestradiol; Levonorgestrel

Indexed keywords

CARBOHYDRATE; ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN C; SEX HORMONE BINDING GLOBULIN;

ADULT; ARTICLE; BONE METABOLISM; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; FEMALE; HEMOSTASIS; HUMAN; METABOLIC PARAMETERS; ORAL CONTRACEPTION; PRIORITY JOURNAL;

ADULT; BONE REMODELING; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; LIPIDS; MIDDLE AGED; SEX HORMONE-BINDING GLOBULIN; TRIGLYCERIDES; WOMEN'S HEALTH; YOUNG ADULT;

EID: 79952980493     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2011.556761     Document Type: Article

References (18)

1. Machado RB, Fabrini P, Cruz AM, et al. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception 2004;70:365-70. (Pubitemid 39422512)
2. Machado RB, De Melo NR, Maia H, Jr., et al. Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles. Contraception 2010;81:102-6.
3. Teichmann A, Apter D, Emerich J, et al. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: Efficacy, safety and bleeding in a randomized, open-label trial. Contraception 2009;80:504-11.
4. Hanley AJ, Williams K, Stern MP, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care 2002;25:1177-84. (Pubitemid 41071169)
5. Kemmeren JM, Algra A, Grobbee DE. Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. J Intern Med 2001;250:441-8. (Pubitemid 32989600)
6. Burkman RT. Lipid metabolism effects with desogestrelcontaining oral contraceptives. Am J Obstet Gynecol 1993;168:1033-40. (Pubitemid 23094299)
7. Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception 1998;57:189-201. (Pubitemid 29281905)
8. Endrikat J, Klipping C, Cronin M, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 mg ethinyl estradiol and 100 mg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002;65:215-21. (Pubitemid 34258542)
9. Scharnagl H, Petersen G, Nauck M, et al. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 2004;69:105-13. (Pubitemid 38167459)
10. Young RL, DelConte A. Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four-month clinical trial. Am J Obstet Gynecol 1999;181:S59-S62.
11. Skouby SO, Endrikat J, Dusterberg B, et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 mg ethinyl estradiol combined with 100 mg levonorgestrel. Contraception 2005;71:111-7. (Pubitemid 40222063)
12. Kiran G, Kiran H, Ekerbicer HC. Serum lipid and lipoprotein changes induced by preparations containing low-dose ethinyl estradiol plus levonorgestrel. Aust NZ J Obstet Gynecol 2003;43:145-7. (Pubitemid 36626119)
13. Lamarche B, Moorjani S, Cantin B, et al. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997;17:1098-105. (Pubitemid 27260329)
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285: 2486-97
15. Odlind V, Milsom I, Persson I, et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482-90.
16. Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173-85.
17. Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 ug/20 ug versus triphasic norethindrone/ethinylestradiol 500-750-1000 ug/35 ug: a multicenter, randomized, open-label study. Eur J Contracept Reprod Health Care 1999;4:75-83. (Pubitemid 29318066)
18. Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 mg levonorgestrel and 20 mg ethinyl estradiol (Alesse). Am J Obstet Gynecol 1999;181:S39-S44.